BiotechTube

Ramipril

ApprovedUNKNOWN
0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Essential Hypertension

Conditions

Essential Hypertension

Trial Timeline

Jun 1, 2006 → Jun 1, 2007

NCT ID
NCT00366119

About Ramipril

Ramipril is a approved stage product being developed by Pacific Biosciences for Essential Hypertension. The current trial status is unknown. This product is registered under clinical trial identifier NCT00366119. Target conditions include Essential Hypertension.

What happened to similar drugs?

14 of 20 similar drugs in Essential Hypertension were approved

Approved (14) Terminated (2) Active (6)
✅Telmisartan/Amlodipine/Chlorthalidone 40/5/12.5 mg + Telmisartan/Amlodipine/Hydrochlorothiazide 40/5/25 mgYuhanApproved
✅Anagre Cap.YuhanApproved
✅olmesartan medoxomil + hydrochlorothiazide, if necessary + amlodipine, if necessaryDaiichi SankyoApproved
✅olmesartan medoxomil + hydrochlorothiazide, if necessary + amlodipine, if necessaryDaiichi SankyoApproved
✅Atenolol + olmesartan medoxomilDaiichi SankyoApproved
✅Arotinolol Hydrochloride + Metoprolol succinate sustained-release tabletSumitomo PharmaApproved
✅Aliskiren + Hydrochlorothiazide + AmlodipineNovartisApproved

Hype Score Breakdown

Clinical
20
Activity
4
Company
5
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00366119ApprovedUNKNOWN

Competing Products

20 competing products in Essential Hypertension

See all competitors
ProductCompanyStageHype Score
L04RD1 + L04TD3CelltrionPhase 1
29
Azilsartan MedoxomilCelltrionPre-clinical
26
AZM X mg + AML Y mg + AZM X mg + AML Y' mg + AZM X' mg + AML Y mg + AZM X' mg + AML Y' mg + AZM X mg + AZM X' mg + AML Y mg + AML Y' mgCelltrionPhase 3
40
Telmisartan/Amlodipine/Chlorthalidone 40/5/12.5 mg + Telmisartan/Amlodipine/Hydrochlorothiazide 40/5/25 mgYuhanApproved
47
Anagre Cap.YuhanApproved
43
Telmisartan/Amlodipine/Chlorthalidone(Truset)YuhanPre-clinical
30
olmesartan medoxomil (OM)/hydrochlorothiazide (HCTZ) tablets and placebo + olmesartan medoxomil (OM)/hydrochlorothiazide (HCTZ) tablets + olmesartan medoxomil/hydrochlorothiazide tablets + olmesartan medoxomil/hydrochlorothiazide tabletsDaiichi SankyoPhase 3
40
olmesartan medoxomil + hydrochlorothiazide, if necessary + losartan + hydrochlorothiazide, if necessaryDaiichi SankyoPhase 3
40
CS8635 20/5/12.5mg and placebo + Olmetec® Plus 20/12.5mg and placeboDaiichi SankyoPhase 3
40
CS-3150 + olmesartan medoxomilDaiichi SankyoPre-clinical
26
olmesartan medoxomil + amlodipine + hydroclororthiazide + placebo + Olmesartan medoxomil + amlodipine + hydrochlorothiazide + placebo + olmesartan medoxomil + amlodipine + hydroclororthiazide + olmesartan medoxomil + amlodipine + hydroclororthiazide + olmesartan medoxomil + amlodipine + hydroclororthiazide + olmesartan medoxomil + amlodipine + olmesartan medoxomil + amlodipine + olmesartan medoxomil + amlodipineDaiichi SankyoPhase 3
40
Olmesartan medoxomil + Atenolol + Hydrochlorothiazide + olmesartan medoxomil + atenololDaiichi SankyoPhase 3
40
olmesartan medoxomil + hydrochlorothiazide, if necessary + amlodipine, if necessaryDaiichi SankyoApproved
43
CS-3150 + EplerenoneDaiichi SankyoPhase 3
40
olmesartan medoxomil + losartan potassiumDaiichi SankyoPhase 3
40
Olmesartan medoxomil 40 mg - Amlodipine 10 mg + Olmesartan 40mg-Amlodipine 10mg-Hydrochlorothiazide 12.5mg + Olmesartan 40mg-Amlodipine 10mg-Hydrochlorothiazide 25mg + OLM 40mg-AML 10mg-Hydrochlorothiazide 12.5mg + OLM 40mg-AML 10mg-Hydrochlorothiazide 12.5mg + OLM 40mg-AML 10mg-Hydrochlorothiazide 25mgDaiichi SankyoPhase 3
40
olmesartan medoxomil + hydrochlorothiazide, if necessary + amlodipine, if necessaryDaiichi SankyoApproved
43
Olmesartan medoxomil + Losartan + Furosemide oral tabletsDaiichi SankyoPhase 3
40
olmesartan medoxomil (OM)+ hydrochlorothiazide (HCTZ) tablets + olmesartan medoxomil (OM)/ hydrochlorothiazide (HCTZ) 20mg/25mgDaiichi SankyoPhase 3
40
olmesartan medoxomil + amlodipineDaiichi SankyoPhase 3
40